查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1407316

特发性肺纤维化市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按药物类型、给药途径、配销通路、地区和竞争细分

Idiopathic Pulmonary Fibrosis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Type, By Route of Administration, by Distribution Channel, by region, and Competition
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年，全球特发性肺纤维化市场价值为 37.6 亿美元，预计在预测期内将出现令人印象深刻的成长，到 2028 年复合CAGR为6.38%。特发性肺纤维化(IPF ) 是一种危险的肺部疾病。当您吸气时，氧气会透过肺部的小气囊进入您的血液。然后它会进入您的内部器官。由于 IPF，您的肺部会充满疤痕组织。随着时间的推移，情况会变得更糟。就像割伤后皮肤上留下的疤痕一样，IPF 疤痕组织也很緻密。它会抑制氧气从肺部转移到血液，这可能会妨碍您的身体正常运作。特发性肺纤维化可以存在很长时间而不出现任何症状。当某人接触污染、某些药物或疾病等情况时，他们可能会出现肺纤维化。不过，医师并不确定 IPF 的病因。

诊断 IPF 需要结合病史、身体检查、肺功能测试、高解析度电脑断层扫描 (HRCT) 扫描，在某些情况下还需要进行肺活检。 IPF 通常很难诊断，因为其症状可能与其他肺部疾病的症状重迭。改进的诊断技术，例如高解析度电脑断层扫描 (HRCT) 和生物标记识别，可以更早、更准确地检测 IPF。这增加了寻求治疗的患者数量。针对 IPF 的新药物和疗法的持续研究和开发导致了新疗法的引入，从而扩大了患者的选择范围。创新疗法的批准是市场的驱动力。关于 IPF 症状和早期诊断重要性的认识活动和教育活动的增加导致更多患者寻求医疗照护。医疗保健专业人员也更有能力识别这种疾病。专注于以患者为中心的护理，包括支持小组、患者宣传和改善 IPF 患者的生活质量，已成为市场的驱动因素。病患权益组织在提高意识和改善病患照护方面发挥着至关重要的作用。

主要市场驱动因素

市场概况
预测期 2024-2028
2022 年市场规模 37.6亿美元
2028 年市场规模 54.2亿美元
2023-2028 年CAGR 6.38%
成长最快的细分市场 网路药局
最大的市场 北美洲

诊断的进步

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球特发性肺纤维化市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型（吡非尼酮、尼达尼布等）
    • 依给药途径（肠胃外、口服、其他）
    • 按配销通路（医院药房、零售药房、网路药房）
    • 按地区
    • 按公司划分 (2022)
  • 市场地图

第 6 章：亚太地区特发性肺纤维化市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型
    • 依给药途径
    • 按配销通路
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国特发性肺纤维化
    • 印度特发性肺纤维化
    • 澳洲特发性肺纤维化
    • 日本特发性肺纤维化
    • 韩国特发性肺纤维化

第 7 章：欧洲特发性肺纤维化市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型
    • 依给药途径
    • 按配销通路
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 西班牙
    • 义大利
    • 英国

第 8 章：北美特发性肺纤维化市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型
    • 依给药途径
    • 按配销通路
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 9 章：南美洲特发性肺纤维化市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型
    • 依给药途径
    • 按配销通路
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲特发性肺纤维化市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型
    • 依给药途径
    • 按配销通路
    • 按国家/地区
  • MEA：国家分析
    • 南非特发性肺纤维化
    • 沙乌地阿拉伯特发性肺纤维化
    • 阿联酋特发性肺纤维化

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 最近的发展
  • 产品发布
  • 併购

第 13 章：全球特发性肺纤维化市场：SWOT 分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第 15 章：大环境分析

第16章：竞争格局

  • 勃林格殷格翰
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • F.霍夫曼-拉罗氏股份公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 西普拉有限公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 盐野义工业株式会社
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 百时美施贵宝公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 联合治疗公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 纤维根公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 顺从疗法
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 盖莱克托公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • CSL贝林
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis

第 17 章：策略建议

第 18 章：关于我们与免责声明

简介目录
Product Code: 19233

Global Idiopathic Pulmonary Fibrosis Market has valued at USD 3.76 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 6.38% through 2028. The lung condition idiopathic pulmonary fibrosis (IPF) is dangerous. When you breathe in, oxygen enters your bloodstream through small air sacs in your lungs. It then makes its way to your inside organs. Your lungs get congested with scar tissue because of IPF. With time, it becomes worse. Like the scars you receive on your skin after a cut, the IPF scar tissue is dense. It inhibits the transfer of oxygen from your lungs to your blood, which might prevent your body from functioning properly. Idiopathic pulmonary fibrosis can exist for a very long time without any symptoms showing up. When someone is exposed to anything like pollution, certain medications, or an illness, they may develop pulmonary fibrosis. Doctors are unsure of what causes IPF, though.

Diagnosing IPF involves a combination of medical history, physical examination, lung function tests, high-resolution computed tomography (HRCT) scans, and, in some cases, a lung biopsy. IPF is often challenging to diagnose because its symptoms can overlap with those of other lung diseases. Improved diagnostic techniques, such as high-resolution computed tomography (HRCT) and the identification of biomarkers, have enabled earlier and more accurate detection of IPF. This has increased the number of patients seeking treatment. The ongoing research and development of new drugs and therapies for IPF have led to the introduction of novel treatments, which expand the available options for patients. The approval of innovative therapies is a driving force in the market. Increased awareness campaigns and educational initiatives about IPF symptoms and the importance of early diagnosis have resulted in more patients seeking medical care. Healthcare professionals are also better equipped to recognize the disease. The focus on patient-centered care, including support groups, patient advocacy, and improving the quality of life for IPF patients, has become a driving factor in the market. Patient advocacy organizations play a crucial role in raising awareness and improving patient care.

Key Market Drivers

Market Overview
Forecast Period2024-2028
Market Size 2022USD 3.76 Billion
Market Size 2028USD 5.42 Billion
CAGR 2023-20286.38%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America

Advancements in Diagnosis

High-Resolution Computed Tomography (HRCT) imaging has become a gold standard in diagnosing IPF. It provides detailed images of the lungs, allowing healthcare professionals to detect characteristic patterns of fibrosis. HRCT is non-invasive and has significantly improved the accuracy of IPF diagnosis. Ongoing research into biomarkers, such as specific proteins or genetic markers, has the potential to aid in early diagnosis and disease monitoring. Identifying biomarkers associated with IPF can help distinguish it from other lung conditions. Minimally invasive lung biopsy techniques, such as transbronchial cryobiopsy and endobronchial ultrasound-guided biopsy, offer alternatives to traditional surgical biopsies. These techniques provide tissue samples for analysis, aiding in the confirmation of IPF diagnosis.

Multi-Disciplinary Discussion (MDD) approach involves a team of specialists, including radiologists, pulmonologists, and pathologists, who jointly evaluate patient data, imaging, and biopsy results. This collaborative approach enhances the accuracy of IPF diagnosis. AI and machine learning algorithms have been applied to HRCT scans and other patient data to improve diagnostic accuracy. These technologies can assist in identifying patterns and characteristics of IPF that may be missed by human observers. Telemedicine has become a valuable tool, especially during the COVID-19 pandemic. It allows healthcare professionals to remotely assess patients, review diagnostic images, and provide consultation for individuals in remote or underserved areas. Genetic testing for specific gene mutations associated with familial IPF can help confirm the diagnosis in cases where a family history of the disease is present. International guidelines and consensus statements, such as those from the American Thoracic Society (ATS) and the European Respiratory Society (ERS), have provided standardized criteria for diagnosing IPF, facilitating consistency in diagnosis. Improved understanding of the clinical presentation and symptoms of IPF has enabled healthcare providers to diagnose the disease more accurately. Common symptoms include progressive breathlessness and dry cough. Bronchoalveolar Lavage (BAL) is a diagnostic procedure that involves collecting fluid from the air sacs in the lungs. It can help rule out other lung diseases and contribute to the diagnostic process. This factor will help in the development of the Global Idiopathic Pulmonary Fibrosis Market.

Increasing Drug Development and Approval

The introduction of new IPF drugs provides healthcare professionals with a broader range of treatment options. This is particularly important because IPF is a complex and progressive disease with limited available therapies. Ongoing research and development efforts aim to improve the efficacy of IPF treatments. New drugs often offer better outcomes, slowing the progression of fibrosis and improving lung function, which can significantly benefit patients. The availability of new, effective medications increases patient access to treatments that may improve their quality of life. It can also be especially important for patients who have not responded well to existing therapies. The entry of new drugs into the market creates competition, potentially leading to price reductions and improved access for patients. Competition can also drive pharmaceutical companies to develop more innovative and effective treatments. The IPF market generates significant revenue, and the development of new drugs represents a substantial economic opportunity for pharmaceutical companies. This financial incentive encourages research and development in the field.

Drug development for IPF often involves clinical trials, which can contribute to the growth of the IPF market. Clinical trials provide opportunities for patients to access cutting-edge treatments and therapies. Regulatory approvals from agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are essential for the market. Approvals signify the safety and efficacy of new treatments, instilling confidence in healthcare providers and patients. As new drugs receive approvals, they often become available in various regions around the world. This expansion contributes to the global growth of the IPF market. Collaborative efforts between pharmaceutical companies, research institutions, and academic centers help advance drug development and bring innovative therapies to the market. New treatments aim not only to slow the progression of IPF but also to improve patients' quality of life by reducing symptoms and increasing functional capacity. With the introduction of new treatments, the IPF market expands, creating opportunities for healthcare professionals, drug manufacturers, and related services. This factor will pace up the demand of the Global Idiopathic Pulmonary Fibrosis Market

Growing Demand of Biologics and Targeted Therapies

Biologics and targeted therapies are designed to target specific disease pathways or mechanisms. They offer a more personalized and precise approach to treating IPF, potentially improving treatment outcomes. Compared to broad-spectrum medications, biologics and targeted therapies may have fewer side effects because they specifically target the underlying causes of the disease. This can lead to improved tolerability and patient compliance. Targeted therapies are often developed based on a deep understanding of the molecular mechanisms of IPF. This leads to treatments that can be highly effective in managing the disease, which is particularly important for a condition with limited treatment options. Biologics and targeted therapies have the potential to modify the course of the disease, slowing down or even halting the progression of fibrosis. This can significantly improve the prognosis for IPF patients.

The introduction of biologics and targeted therapies expands the IPF market by providing new treatment options. This contributes to the overall growth of the market and may encourage further research and development in the field. Increasing availability of biologics and targeted therapies enhances patient access to innovative treatments. This can be especially important for patients who do not respond well to traditional therapies. The entry of biologics and targeted therapies into the market creates competition, which can lead to price reductions, improving affordability and access for patients. Regulatory approvals for these therapies signify their safety and efficacy. These approvals build confidence among healthcare providers and patients, driving demand. As biologics and targeted therapies receive approvals, they often become available in various regions worldwide, contributing to the global expansion of the IPF market. Collaborative efforts between pharmaceutical companies, research institutions, and academic centers are essential for the development of biologics and targeted therapies. These efforts help advance research and bring innovative treatments to the market. This factor will accelerate the demand of the Global Idiopathic Pulmonary Fibrosis Market

Key Market Challenges

High Cost of Treatment

Idiopathic Pulmonary Fibrosis (IPF) is a chronic and often progressive disease that requires long-term treatment. The high cost of medications, therapy, and healthcare services can impose a substantial financial burden on patients and their families, potentially leading to financial stress. Some IPF treatments, especially newer and more advanced therapies, may not be fully covered by health insurance plans. This can result in out-of-pocket expenses for patients, making it difficult for them to access necessary treatments. The high cost of IPF treatment can create disparities in access to care. Patients with limited financial resources may face barriers to accessing the most effective therapies, leading to disparities in outcomes. The cost of treatment can impact patients' adherence to prescribed medications and therapies. Patients may reduce or skip doses due to cost concerns, which can affect the effectiveness of the treatment. The high cost of IPF treatment places a financial burden on healthcare systems and insurance providers, potentially limiting the availability of certain treatments or leading to increased healthcare costs for society. High treatment costs can lead to financial toxicity, which has a negative impact on patients' overall well-being. This can include increased stress, anxiety, and reduced quality of life. Pharmaceutical companies face significant research and development costs when developing new IPF treatments. The high cost of development and regulatory approval can contribute to the high prices of these therapies once they reach the market. High costs can lead some patients to discontinue or delay their treatment, which may result in disease progression and more severe health outcomes.

Limited Treatment Options

Idiopathic Pulmonary Fibrosis (IPF) is a progressive and often fatal lung disease, and the limited treatment options mean that many patients have few options to slow down or halt the progression of the disease. This can result in a poor prognosis for those affected. The limited number of effective therapies for IPF can leave healthcare providers with few tools to manage the disease. This can lead to a sense of frustration when trying to provide the best care for their patients.

Patients diagnosed with IPF may experience significant frustration and anxiety when they learn about the limited treatment options. This can affect their mental and emotional well-being. The lack of specific treatments for IPF can sometimes result in delayed diagnosis as healthcare providers rule out other conditions. This can lead to lost time for early intervention. Managing symptoms and improving the quality of life for IPF patients can be challenging due to the limited therapeutic options. This leaves many patients dealing with breathlessness, cough, and fatigue without effective relief. The limited treatment options can lead to treatment gaps where patients may not have appropriate therapies to manage the disease. This can result in a poor overall patient experience. The lack of effective treatments may also limit the incentives for pharmaceutical companies to invest in IPF research and development, potentially slowing the pace of innovation. The limited treatment options highlight significant unmet medical needs in the IPF field. There is a clear need for more effective therapies to address this devastating condition. The limited treatment options can place a burden on healthcare systems as they struggle to manage the disease and provide care for patients with few effective options.

Key Market Trends

Research into Genetic and Environmental Factors

Research into genetic factors helps identify individuals who may be at a higher risk of developing IPF. This knowledge can lead to personalized screening and preventative strategies. Genetic and environmental research may reveal biomarkers that can be used for early detection and diagnosis of IPF, enabling healthcare providers to intervene at an earlier, potentially more treatable stage of the disease. Identifying genetic and environmental risk factors allows for risk assessment and counseling for individuals with a family history of IPF or who have been exposed to certain environmental triggers.

Genetic research can help identify specific pathways and mechanisms underlying IPF. This knowledge may lead to the development of targeted therapies that address the root causes of the disease. Understanding the genetic and environmental factors contributing to an individual's IPF can inform the development of personalized treatment plans, optimizing therapy for each patient's unique needs. Research into environmental factors, such as exposure to certain toxins or pollutants, can help identify strategies for reducing exposure and preventing the development or exacerbation of IPF. Patients with IPF may benefit from genetic counseling to understand the hereditary aspects of the disease, particularly in cases of familial IPF. Insights gained from genetic and environmental research can uncover novel therapeutic targets, which may lead to the development of innovative treatments for IPF.

Segmental Insights

Drug Type Insights

In 2022, the Global Idiopathic Pulmonary Fibrosis Market largest share was held by pirfenidone segment and is predicted to continue expanding over the coming years. Pirfenidone has been proven effective in slowing the progression of IPF and improving lung function in some patients. It was one of the first drugs to receive approval for the treatment of IPF, which has contributed to its market dominance. It was among the early entrants into the IPF market, receiving approval in certain regions ahead of other treatments. Its early introduction gave it a head start in market penetration. Pirfenidone has a long history in the IPF market. It was one of the first drugs available for the condition, and this extended presence has established its reputation and familiarity among healthcare professionals and patients. It has also gained regulatory approvals in various countries, contributing to its market dominance. These approvals have expanded its global reach and market share. Over the years, clinical trials and real-world data have provided substantial evidence supporting the efficacy of pirfenidone in managing IPF. This data has reinforced its use as a standard treatment option.

Distribution Channel Insights

In 2022, the Global Idiopathic Pulmonary Fibrosis Market largest share was held by hospital pharmacies segment in the forecast period and is predicted to continue expanding over the coming years. In some regions, a significant proportion of IPF patients receive treatment on an inpatient basis, particularly during acute exacerbations or advanced stages of the disease. Hospital pharmacies are responsible for dispensing and managing medications for these inpatients. Hospitals often play a key role in conducting clinical trials for new IPF treatments. The distribution and management of trial medications may involve hospital pharmacies. IPF treatment can involve complex medication regimens, including the use of oxygen therapy, immunosuppressive drugs, and other specialized medications. Hospital pharmacies are equipped to handle these complex regimens. Regional healthcare regulations and reimbursement policies can influence the distribution of medications. In some cases, regulations or policies may favour or require hospital-based distribution of certain medications.

Regional Insights

The North America region dominates the Global Idiopathic Pulmonary Fibrosis Market in 2022. North America, particularly the United States and Canada, boasts well-developed and advanced healthcare infrastructure. This includes a network of specialized treatment centers, experienced healthcare professionals, and state-of-the-art medical facilities. These resources are essential for the diagnosis and management of IPF. North America has implemented screening programs and awareness campaigns that contribute to early diagnosis of IPF. Early detection is crucial for effective management and treatment of the disease. The region is a hub for pharmaceutical and biotechnology companies involved in the research and development of IPF treatments. This has led to a greater number of clinical trials and innovative therapies being available in North America. North America often has earlier access to newly approved IPF drugs and therapies. Regulatory agencies like the U.S. Food and Drug Administration (FDA) have expedited review processes for certain IPF treatments, which accelerates their availability in the market.

Key Market Players

Boehringer Ingelheim

F. Hoffmann-La Roche AG

Cipla Ltd.

Shionogi & Co., Ltd.

Bristol-Myers Squibb Co.

United Therapeutics

FibroGen, Inc.

Pliant Therapeutics

Galecto Inc.

CSL Behring

Report Scope:

In this report, the Global Idiopathic Pulmonary Fibrosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Idiopathic Pulmonary Fibrosis Market, By Drug Type:

  • Pirfenidone
  • Nintedanib
  • others
  • Idiopathic Pulmonary Fibrosis Market, By Route of Administration
  • Oral
  • Parenteral
  • Others

Idiopathic Pulmonary Fibrosis Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Idiopathic Pulmonary Fibrosis Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies presents in the Global Idiopathic Pulmonary Fibrosis Market.

Available Customizations:

  • Global Idiopathic Pulmonary Fibrosis Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Idiopathic Pulmonary Fibrosis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Pirfenidone, Nintedanib, others)
    • 5.2.2. By Route of Administration (Parenteral, Oral, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Market Map

6. Asia Pacific Idiopathic Pulmonary Fibrosis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Idiopathic Pulmonary Fibrosis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. India Idiopathic Pulmonary Fibrosis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Australia Idiopathic Pulmonary Fibrosis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel
    • 6.3.4. Japan Idiopathic Pulmonary Fibrosis Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Drug Type
        • 6.3.4.2.2. By Route of Administration
        • 6.3.4.2.3. By Distribution Channel
    • 6.3.5. South Korea Idiopathic Pulmonary Fibrosis Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Drug Type
        • 6.3.5.2.2. By Route of Administration
        • 6.3.5.2.3. By Distribution Channel

7. Europe Idiopathic Pulmonary Fibrosis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Idiopathic Pulmonary Fibrosis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Germany Idiopathic Pulmonary Fibrosis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Spain Idiopathic Pulmonary Fibrosis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Idiopathic Pulmonary Fibrosis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. United Kingdom Idiopathic Pulmonary Fibrosis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Distribution Channel

8. North America Idiopathic Pulmonary Fibrosis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Idiopathic Pulmonary Fibrosis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Mexico Idiopathic Pulmonary Fibrosis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Canada Idiopathic Pulmonary Fibrosis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel

9. South America Idiopathic Pulmonary Fibrosis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Idiopathic Pulmonary Fibrosis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Argentina Idiopathic Pulmonary Fibrosis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Colombia Idiopathic Pulmonary Fibrosis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Idiopathic Pulmonary Fibrosis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Idiopathic Pulmonary Fibrosis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Saudi Arabia Idiopathic Pulmonary Fibrosis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. UAE Idiopathic Pulmonary Fibrosis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Idiopathic Pulmonary Fibrosis Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. Boehringer Ingelheim
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. F. Hoffmann-La Roche AG
    • 16.2.1. Business Overview
    • 16.2.2. Company Snapshot
    • 16.2.3. Products & Services
    • 16.2.4. Financials (In case of listed companies)
    • 16.2.5. Recent Developments
    • 16.2.6. SWOT Analysis
  • 16.3. Cipla Ltd
    • 16.3.1. Business Overview
    • 16.3.2. Company Snapshot
    • 16.3.3. Products & Services
    • 16.3.4. Financials (In case of listed companies)
    • 16.3.5. Recent Developments
    • 16.3.6. SWOT Analysis
  • 16.4. Shionogi & Co., Ltd.
    • 16.4.1. Business Overview
    • 16.4.2. Company Snapshot
    • 16.4.3. Products & Services
    • 16.4.4. Financials (In case of listed companies)
    • 16.4.5. Recent Developments
    • 16.4.6. SWOT Analysis
  • 16.5. Bristol-Myers Squibb Co.
    • 16.5.1. Business Overview
    • 16.5.2. Company Snapshot
    • 16.5.3. Products & Services
    • 16.5.4. Financials (In case of listed companies)
    • 16.5.5. Recent Developments
    • 16.5.6. SWOT Analysis
  • 16.6. United Therapeutics
    • 16.6.1. Business Overview
    • 16.6.2. Company Snapshot
    • 16.6.3. Products & Services
    • 16.6.4. Financials (In case of listed companies)
    • 16.6.5. Recent Developments
    • 16.6.6. SWOT Analysis
  • 16.7. FibroGen, Inc
    • 16.7.1. Business Overview
    • 16.7.2. Company Snapshot
    • 16.7.3. Products & Services
    • 16.7.4. Financials (In case of listed companies)
    • 16.7.5. Recent Developments
    • 16.7.6. SWOT Analysis
  • 16.8. Pliant Therapeutics
    • 16.8.1. Business Overview
    • 16.8.2. Company Snapshot
    • 16.8.3. Products & Services
    • 16.8.4. Financials (In case of listed companies)
    • 16.8.5. Recent Developments
    • 16.8.6. SWOT Analysis
  • 16.9. Galecto Inc.
    • 16.9.1. Business Overview
    • 16.9.2. Company Snapshot
    • 16.9.3. Products & Services
    • 16.9.4. Financials (In case of listed companies)
    • 16.9.5. Recent Developments
    • 16.9.6. SWOT Analysis
  • 16.10. CSL Behring
    • 16.10.1. Business Overview
    • 16.10.2. Company Snapshot
    • 16.10.3. Products & Services
    • 16.10.4. Financials (In case of listed companies)
    • 16.10.5. Recent Developments
    • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer